ADMA

ADMA BiologicsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$12.30

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$10.84

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$7.50

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-17

AI commentary

News tone is constructive on Asceniv growth, margin expansion, and reiterated guidance, but mixed because Q2 revenue reportedly missed consensus and Bivigam remained weak [#PR-EARNINGS-2026-08-06]. Social coverage is unavailable, and missing analyst reaction is not treated as positive evidence. The setup is positive but monitoring-oriented.

RankAlpha Sentiment Codex - 2026-08-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-15eventACAAI real-world evidence updateMedium impact

ADMA submitted an abstract based on 127 Asceniv-treated primary-immunodeficiency patients reporting statistically significant reductions in infection-related hospitalizations and healthcare utilization. Positive reception could support payer and prescriber adoption [#SEC-8K-2026-08-05].

2026-12-31eventAsceniv growth and FY2026 guidance executionHigh impact

Q2 2026 revenue was $124.4 million, Asceniv revenue grew 24% year over year to $102.9 million, gross margin reached 69%, and FY2026 guidance was reiterated at $530-$560 million revenue and $265-$300 million adjusted EBITDA. Continued Asceniv utilization and margin delivery are the nearest rerating tests [#SEC-8K-2026-08-05].

2026-12-31catalystBivigam competitive and pricing pressureHigh impact

Bivigam remains exposed to competitive dynamics, discounting, and pricing pressure in the standard immune-globulin market. Stabilization could fail to hold, leaving Asceniv to carry more of the growth burden [#SEC-8K-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-17 • Updated nightlySource: Internal modelMethodology